**Fortune 2024 Ranking: Gilead Sciences**

Gilead Sciences, an American multinational pharmaceutical corporation, ranks 154th in the Fortune 2024 list, a four-position decline from its previous standing. Headquartered in Foster City, California, the company operates in the Health Care sector, specifically in the pharmaceutical industry. As of March 28, 2024, Gilead Sciences boasts a market value of $91,340.5 million and a market capitalization of $91,341 million, as updated on June 4, 2024.

Founded by a group of individuals, the company's leadership is currently headed by Daniel P. O'Day, who serves as the Chief Executive Officer. Notably, the company's founder is not the current CEO, and the CEO is not female. Despite this, Gilead Sciences has demonstrated a growth in jobs, showcasing its commitment to expanding its workforce.

In terms of financial performance, Gilead Sciences reported revenues of $27,116 million in the fiscal year, representing a modest decline of 0.6% compared to the previous year. However, the company's profits experienced a significant increase of 23.4%, reaching $5,665 million. The company's total assets stood at $62,125 million, underscoring its substantial presence in the pharmaceutical industry.

With a workforce of approximately 18,000 employees, Gilead Sciences is a prominent player in the global pharmaceutical market. The company's financial performance and employee growth have contributed to its consistent presence in the Fortune rankings. Although it has dropped in rank this year, Gilead Sciences remains a notable presence in the industry.

As a publicly traded company, Gilead Sciences is listed on the stock exchange under the ticker symbol GILD. Its commitment to growth and innovation in the pharmaceutical sector has established it as a key player in the Health Care industry. For more information about the company, investors and stakeholders can visit its official website at https://www.gilead.com.